Advertisement

Medical Approaches to Weight-Centric Management of Obese Patients with Type 2 Diabetes

  • Donna H. Ryan

Abstract

The traditional approach to management of type 2 diabetes has been targeting both glycemic control and associated risk factors that drive cardiovascular disease risk (blood pressure, dyslipidemia, pro-thrombotic tendency). The primary focus of this chapter is to explore the role of medical approaches (as opposed to surgical approaches) using lifestyle intervention to achieve weight management as a pathway to improving the metabolic profile, symptoms, and functionality of patients with type 2 diabetes. The chapter will review the evidence for health benefit from medically induced weight loss in persons with type 2 diabetes, and will limit its scope to interventions that use lifestyle alone, without adjunctive medications.

Keywords

Type 2 diabetes Glycemic control Lifestyle intervention Metabolic profile 

References

  1. 1.
    Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez G, Davidson MH, American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19 Suppl 1:1–48.CrossRefGoogle Scholar
  2. 2.
    The Look AHEAD Research Group. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials. 2003;24(5):610–28.CrossRefGoogle Scholar
  3. 3.
    The Look AHEAD Research Group. Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) research study. Diab Vasc Dis Res. 2006;3(3):202–15.PubMedCentralCrossRefGoogle Scholar
  4. 4.
    The Look AHEAD Research Group. The Look AHEAD Study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring). 2006;14(5):737–52.CrossRefGoogle Scholar
  5. 5.
    The Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD Study. Obesity. 2014;22:5–13.PubMedCentralCrossRefGoogle Scholar
  6. 6.
    Guare JC, Wing RR, Grant A. Comparison of obese NIDDM and nondiabetic women: short- and long-term weight loss. Obes Res. 1995;3:329–35.PubMedCrossRefGoogle Scholar
  7. 7.
    Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacologic management of obesity: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–62.Google Scholar
  8. 8.
    Wadden T, West D, Neiberg R, The Look AHEAD Research Group, et al. One-year weight losses in the Look AHEAD study: factors associated with success. Obesity. 2009;17(4):713–22.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Espeland M, Bray G, Neiberg R, The Look AHEAD Research Group, et al. Describing patterns of weight changes using principal components analysis: results from the Action for Health in Diabetes (Look AHEAD) research group. Ann Epidemiol. 2009;19(10):701–10.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    The Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30(6):1374–83.CrossRefGoogle Scholar
  11. 11.
    The Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four year results of the Look AHEAD trial. Arch Intern Med. 2010;170(17):1566–75.PubMedCentralGoogle Scholar
  12. 12.
    Wadden T, Neiberg R, Wing R, The Look AHEAD Research Group, et al. Four-year weight losses in the Look AHEAD study: factors associated with success. Obesity. 2011;19(10):1987–98.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Unick J, Beavers D, Jakicic J, The Look AHEAD Research Group, et al. The effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial. Diabetes Care. 2011;34(10):2152–7.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Unick JL, Beavers D, Bond DS, et al. The long-term effectiveness of a lifestyle intervention in severely obese individuals. Am J Med. 2013;126:236–42.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–54.PubMedCentralCrossRefGoogle Scholar
  16. 16.
    Sjostrom L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56–65.PubMedCrossRefGoogle Scholar
  17. 17.
    Sjostrom L, Narbro K, Sjostrom D, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.PubMedCrossRefGoogle Scholar
  18. 18.
    Gregg EW, Chen H, Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012;308:2489–96.PubMedCrossRefGoogle Scholar
  19. 19.
    Foster G, Sanders M, Millman R, The Sleep AHEAD Ancillary Study, et al. Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care. 2009;32(6):1017–9.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Kuna ST, Reboussin DM, Borradaile KE, The Sleep AHEAD Research Group of the Look AHEAD Research Group, et al. Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. Sleep. 2013;36(5):641–649A.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Lazo M, Solga S, Horska A, The Fatty Liver Subgroup of the Look AHEAD Research Group, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010;33(10):2156–63.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Crosby. Manual for the IWQOL-LITE measure. www.qualityoflifeconsulting.com. Accessed 10 Sept 2014.
  23. 23.
    Williamson D, Rejeski J, Lang W, The Look AHEAD Research Group, et al. Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes. Arch Intern Med. 2009;169(2):163–71.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–71.PubMedCrossRefGoogle Scholar
  25. 25.
    Faulconbridge L, Wadden T, Rubin R, The Look AHEAD Research Group, et al. One-year changes in symptoms of depression and weight in overweight/obese individuals with type 2 diabetes in the Look AHEAD study. Obesity. 2012;20(4):783–93.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Rejeski WJ, Ip EH, Bertoni AG, et al. Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med. 2012;366:1209–17.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Foy CG, Lewis CE, Hairston KG, The Look AHEAD Research Group, et al. Intensive lifestyle intervention improves physical function among obese adults with knee pain: findings from the Look AHEAD trial. Obesity. 2011;19:83–93. Erratum, Obesity (Silver Spring) 2011;19:233.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Phelan S, Kanaya AM, Subak LL, et al. Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD trial. J Urol. 2012;187:939–44.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Breyer BN, Phelan S, Hogan PE, The Look AHEAD Research Group, et al. Intensive lifestyle intervention reduces urinary incontinence in overweight/obese men with type 2 diabetes: results from the Look AHEAD trial. J Urol. 2014;192(1):144–9.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Wing R, Rosen R, Fava J, Bahnson J, et al. Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial. J Sex Med. 2010;7(1 Pt 1):156–65.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Wing RR, Bond DS, Gendrano IN, The Sexual Dysfunction Subgroup of the Look AHEAD Research Group, et al. Effect of intensive lifestyle intervention on sexual dysfunction in women with type 2 diabetes: results from an ancillary Look AHEAD study. Diab Care. 2013;36:2937–44.CrossRefGoogle Scholar
  32. 32.
    Espeland MA, Glick HA, Bertoni A et al., the Look AHEAD Research Group. Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with Type 2 diabetes. Diabetes Care. 2014;37(9):2548–56.Google Scholar
  33. 33.
    O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20(7):1426–36.PubMedCrossRefGoogle Scholar
  34. 34.
    Garvey WT, Ryan DH, Bohannon NJV, et al. Weight loss therapy in type 2 diabetes: effects of phentermine and topiramate extended-release. Diabetes Care. 2014;37(12):3309–16.PubMedCrossRefGoogle Scholar
  35. 35.
    Hollander P, Gupta AK, Plodkowski R, The COR-Diabetes Study Group, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–9.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    FDA Briefing Document NDA 206321. LIraglutide 3.0 mg. Endocrinologic and Metabolic Advisory Committee. 11 Sept 2014. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM413317.pdf. Accessed 25 Sept 2014.

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Pennington Biomedical Research CenterNew OrleansUSA

Personalised recommendations